Brain Tumor<br><span>Awareness Month</span>

Brain Tumor
Awareness Month

Learn how you can support the brain cancer community throughout the month of May and beyond.

Learn More
the science <br><span>of research</span>

the science
of research

Our Director of Science, Ze’ev Bomzon, discusses his research on Tumor Treating Fields and the importance of effectively explaining the technology.

Learn More
2016 Novocure <br><span>annual report</span>

2016 Novocure
annual report

View our 2016 Annual Report to learn where we've been and where we are headed in 2017 and beyond.

Learn More
innovation <br><span>at work</span>

at work

Our second generation Optune System is smaller and less than half the weight of our first generation Optune System. See more on the innovation behind our redesigned Tumor Treating Fields delivery system.

Learn More


Martin Romero Sanchez, a glioblastoma patient, and his wife, Karma Punwasi, have found support by connecting with other brain cancer survivors and caregivers, along with young adults affected by cancer.

Learn More
working one-on-one <span>with our patients</span>

working one-on-one with our patients

Our Device Support Specialists (DSSs) embody our patient-forward mission and set our business apart from other companies that market cancer therapies.

Learn More

the story
of Novocure

In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with more than 450 employees and operations in the U.S., Europe and Asia.

Learn More

Tumor Treating Fields, or TTFields, are low intensity, alternating electric fields.

TTFields disrupt cancer cell division through physical interactions with key molecules during mitosis. Our non-invasive treatment targets solid tumors.


explore our clinical pipeline.

Our research shows that TTFields have an antimitotic effect in more than 15 solid tumor types in culture and in eight in vivo tumor models.


we are dedicated to improving the lives of cancer patients.

Patients remain at the heart of the work we do every day. Learn more about our patients, their families and the people working to deliver patient-forward therapies to treat cancer.